 |
answer text |
<p>NHS England is engaging with the National Institute for Health and Care Excellence
(NICE) on the Highly Specialised Technologies evaluation of human alpha1-proteinase
inhibitor for treating emphysema in adults with documented severe alpha1 antitrypsin
deficiency. NICE has not yet published final guidance and recently consulted on its
draft guidance.</p><p> </p><p>NICE’s evaluation committee is due to meet again to
consider its recommendations in spring next year. This is to enable the company that
makes the alpha1-proteinase inhibitor to prepare and submit additional information
for consideration by the committee. Once NICE guidance is received, NHS England will
then consider the commissioning implications in consultation with the Specialised
Respiratory Clinical Reference Group.</p>
|
 |
